Changes in Senior Management Personnel
AKUMS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Akums Drugs reported its Q4 and full FY2026 audited results. Standalone revenue grew marginally to ₹13,487 million from ₹13,118 million, but profit after tax fell to ₹1,116 million from ₹1,610 million YoY, with EPS declining from ₹10.76 to ₹7.29. The Board declared a final dividend of ₹1 per share (50%) and a special dividend of ₹2 per share (100%), with record date July 3, 2026. In the senior management change, Mr. V Jagannathan was appointed as President – HR, replacing Mr. Arvind Srivastava who ceased as President – HR effective May 14, 2026. The auditors issued an unmodified report but included an Emphasis of Matter regarding an ongoing Income Tax Department search and seizure operation from January 2025 and subsequent show cause notices, with impact not yet ascertainable.
The profit decline despite flat revenue suggests cost pressures. The HR leadership change appears routine with no governance red flags. The ongoing tax scrutiny is a minor concern but auditors did not modify their opinion.